SCHEMBL990550

SCHEMBL990550

O=C(O)NCCOc1ccc2c(c1)C(C1(c3ccc(F)cc3)CCC1)=NCC2

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
POLB P06746 1/20 0.37
MAOA P21397 2/20 0.34
MAOB P27338 2/20 0.34
DRD2 P14416 1/20 0.34
PPARA Q07869 4/20 0.33
PPARG P37231 3/20 0.33
HCRTR1 O43613 1/20 0.33
ALDH1A1 P00352 1/20 0.33
RAB9A P51151 1/20 0.33
S1PR1 P21453 2/20 0.33
S1PR3 Q99500 2/20 0.33
MAPK14 Q16539 2/20 0.33
MAPK1 P28482 2/20 0.33
CXCR2 P25025 1/20 0.33
P2RX7 Q99572 1/20 0.32
LMNA P02545 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8029267 0.88 PDK2 (0.45) KDM4EPOLBDRD2LMNASMN1; SMN2
SCHEMBL990199 0.87 NPC1 (0.38) KDM4EPOLBMAOAMAOBDRD2
SCHEMBL988866 0.84 MAOB (0.36) MAOAMAOBDRD2ALDH1A1MAPK14
SCHEMBL4407876 0.83 MAOA (0.36) KDM4EPOLBMAOAMAOBDRD2
SCHEMBL989898 0.83 PDK2 (0.39) KDM4EPOLBMAOAMAOBALDH1A1
SCHEMBL15153859 0.82 PDK2 (0.35) KDM4EPOLBMAOAMAOBDRD2
SCHEMBL989150 0.82 SLC6A9 (0.48) KDM4EPOLBMAOAMAOBDRD2
SCHEMBL989560 0.82 F10 (0.42) KDM4ERAB9ASMN1; SMN2
SCHEMBL988967 0.81 KDM4E (0.34) KDM4EPOLBPPARAPPARGRAB9A
SCHEMBL989752 0.81 CYP3A4 (0.37) KDM4EPOLBMAOAMAOBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653100-B2 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2014-02-18 US disclosed
EP-2271625-B1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT GMBH & CO KG (DE) 2012-09-12 EP disclosed
US-20110105502-A1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Abbott BmbH & Co. KG (DE) 2011-05-05 US disclosed
EP-2271625-A2 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Abbott GmbH & Co. KG (DE) 2011-01-12 EP disclosed
WO-2009121872-A2 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT GMBH & CO. KG (DE) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105502-A1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY GOLT1B, SLC10A1, SUGT1 KDM4E 3292/4885POLB 3669/4885MAOA 3531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.